
Desmopressin (dDAVP), a synthetic analog of the neurohypophyseal nonapeptide arginine vasopressin, has enhanced antidiuretic potency, markedly diminished pressor activity, and a prolonged half-life and duration of action compared to the natural hormone. Desmopressin is the treatment of choice for central diabetes insipidus and can be administered either intranasally or parenterally. A newly approved indication is treatment of mild classical hemophilia and von Willebrand's disease, in which deficient concentrations of factor VIII and von Willebrand's factor are transiently increased to levels that allow minor surgery.
Memory Disorders, Drug Synergism, Anemia, Sickle Cell, Enuresis, Hemophilia A, Arginine Vasopressin, Kidney Concentrating Ability, Structure-Activity Relationship, von Willebrand Diseases, Urinary Incontinence, Animals, Humans, Learning, Deamino Arginine Vasopressin, Diabetes Insipidus
Memory Disorders, Drug Synergism, Anemia, Sickle Cell, Enuresis, Hemophilia A, Arginine Vasopressin, Kidney Concentrating Ability, Structure-Activity Relationship, von Willebrand Diseases, Urinary Incontinence, Animals, Humans, Learning, Deamino Arginine Vasopressin, Diabetes Insipidus
| citations The total number of citations received by all articles of the researcher of interest. | 282 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
